MA50156A - Variants d'anticorps - Google Patents

Variants d'anticorps

Info

Publication number: MA50156A
Authority: MA; Morocco
Prior art keywords: antibody variants; variants; antibody
Prior art date: 2017-09-19

Application number

MA050156A

Other languages

English (en)

Inventor

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-19

Filing date

2018-09-11

Publication date

2020-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-09-11 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2020-07-29 Publication of MA50156A publication Critical patent/MA50156A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA050156A 2017-09-19 2018-09-11 Variants d'anticorps MA50156A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP17191989.7A EP3456738A1 (fr)	2017-09-19	2017-09-19	Variantes d'anticorps

Publications (1)

Publication Number	Publication Date
MA50156A true MA50156A (fr)	2020-07-29

Family

ID=59923275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050156A MA50156A (fr)	2017-09-19	2018-09-11	Variants d'anticorps

Country Status (21)

Country	Link
EP (2)	EP3456738A1 (fr)
JP (2)	JP7240385B2 (fr)
KR (1)	KR20200053514A (fr)
CN (1)	CN111094343A (fr)
AR (1)	AR113303A1 (fr)
AU (1)	AU2018337495A1 (fr)
BR (1)	BR112020005482A2 (fr)
CA (1)	CA3075959A1 (fr)
CL (1)	CL2020000721A1 (fr)
CO (1)	CO2020003260A2 (fr)
CR (2)	CR20200132A (fr)
EA (1)	EA202090617A1 (fr)
GE (1)	GEP20237484B (fr)
IL (1)	IL273351A (fr)
JO (1)	JOP20200063A1 (fr)
MA (1)	MA50156A (fr)
MX (1)	MX2020002989A (fr)
PH (1)	PH12020500473A1 (fr)
SG (1)	SG11202002220TA (fr)
TW (1)	TW201915021A (fr)
WO (1)	WO2019057564A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2019001458A (es)	2016-08-02	2019-07-04	Visterra Inc	Polipeptidos modificados y usos de los mismos.
WO2020114616A1 (fr)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2348051T3 (en) *	2003-11-05	2019-03-18	Roche Glycart Ag	CD20 antibodies with increased fc receptor binding affinity and effector function
CA2595112A1 (fr)	2004-12-31	2006-07-13	Genentech, Inc.	Polypeptides de liaison a la br3 et leurs utilisations
CA3086659A1 (fr)	2007-12-26	2009-07-09	Xencor, Inc.	Variants de fc avec une liaison alteree a fcrn
CN107936117B (zh)	2008-06-25	2022-12-23	诺华股份有限公司	抑制TNFα的稳定和可溶的抗体
WO2015158867A1 (fr)	2014-04-16	2015-10-22	Ucb Biopharma Sprl	Protéines fc multimères
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11319383B2 (en) *	2016-03-14	2022-05-03	Universitetet \| Oslo	Engineered immunoglobulins with altered FcRn binding

2017
- 2017-09-19 EP EP17191989.7A patent/EP3456738A1/fr active Pending
2018
- 2018-09-11 JP JP2020516456A patent/JP7240385B2/ja active Active
- 2018-09-11 JO JOP/2020/0063A patent/JOP20200063A1/ar unknown
- 2018-09-11 MX MX2020002989A patent/MX2020002989A/es unknown
- 2018-09-11 CR CR20200132A patent/CR20200132A/es unknown
- 2018-09-11 CA CA3075959A patent/CA3075959A1/fr active Pending
- 2018-09-11 EA EA202090617A patent/EA202090617A1/ru unknown
- 2018-09-11 MA MA050156A patent/MA50156A/fr unknown
- 2018-09-11 SG SG11202002220TA patent/SG11202002220TA/en unknown
- 2018-09-11 EP EP18762890.4A patent/EP3684807A1/fr active Pending
- 2018-09-11 CR CR20210205A patent/CR20210205A/es unknown
- 2018-09-11 GE GEAP201815316A patent/GEP20237484B/en unknown
- 2018-09-11 CN CN201880060497.2A patent/CN111094343A/zh active Pending
- 2018-09-11 BR BR112020005482-8A patent/BR112020005482A2/pt unknown
- 2018-09-11 AU AU2018337495A patent/AU2018337495A1/en active Pending
- 2018-09-11 WO PCT/EP2018/074522 patent/WO2019057564A1/fr active Application Filing
- 2018-09-11 KR KR1020207009263A patent/KR20200053514A/ko not_active Application Discontinuation
- 2018-09-17 TW TW107132681A patent/TW201915021A/zh unknown
- 2018-09-19 AR ARP180102664A patent/AR113303A1/es unknown
2020
- 2020-03-09 PH PH12020500473A patent/PH12020500473A1/en unknown
- 2020-03-17 IL IL273351A patent/IL273351A/en unknown
- 2020-03-19 CO CONC2020/0003260A patent/CO2020003260A2/es unknown
- 2020-03-19 CL CL2020000721A patent/CL2020000721A1/es unknown
2022
- 2022-12-27 JP JP2022210008A patent/JP7402304B2/ja active Active

Also Published As

Publication number	Publication date
IL273351A (en)	2020-05-31
EP3456738A1 (fr)	2019-03-20
SG11202002220TA (en)	2020-04-29
GEP20237484B (en)	2023-03-27
US20200216527A1 (en)	2020-07-09
PH12020500473A1 (en)	2021-01-25
JP7402304B2 (ja)	2023-12-20
CR20200132A (es)	2020-07-24
JP2020534307A (ja)	2020-11-26
CL2020000721A1 (es)	2020-08-07
BR112020005482A2 (pt)	2020-09-29
CO2020003260A2 (es)	2020-04-13
CN111094343A (zh)	2020-05-01
AU2018337495A1 (en)	2020-04-09
EA202090617A1 (ru)	2020-07-27
WO2019057564A1 (fr)	2019-03-28
JP7240385B2 (ja)	2023-03-15
KR20200053514A (ko)	2020-05-18
TW201915021A (zh)	2019-04-16
AR113303A1 (es)	2020-04-08
JOP20200063A1 (ar)	2020-03-17
CA3075959A1 (fr)	2019-03-28
EP3684807A1 (fr)	2020-07-29
JP2023036885A (ja)	2023-03-14
CR20210205A (es)	2021-07-27
MX2020002989A (es)	2020-07-22

Publication	Publication Date	Title
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA49043A (fr)	2020-02-12	Formulation stable d'anticorps
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
MA46041A (fr)	2021-03-24	Anticorps anti-tim -3
MA56006A (fr)	2022-05-04	Formulations sous-cutanées d'anticorps her2
MA50505A (fr)	2020-09-09	Anticorps 2 + 1 bispécifiques (contorsbodies)
MA42924A (fr)	2018-08-01	Variants optimisés d'anticorps anti-vegf
MA44381A (fr)	2019-01-23	Format d'anticorps hétérodimères multispécifiques
MA49749A (fr)	2021-03-24	Anticorps anti-cd137
MA49726A (fr)	2020-06-10	Formulation d'anticorps anti-cgrp
MA45231A (fr)	2021-05-05	Anticorps anti-ige
MA52212A (fr)	2021-02-17	Anticorps multivalent
MA44054A (fr)	2018-10-24	Plateforme d'anticorps bispécifique
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
MA52152A (fr)	2021-01-20	Anticorps
MA42843A (fr)	2018-07-25	Anticorps anti-cd115
MA54052A (fr)	2022-02-09	Formulation d'anticorps
MA54139A (fr)	2021-09-15	Formulation d'anticorps